Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gout drug stop cirrhosis from getting worse?

NCT ID NCT07033533

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether allopurinol can interfere with the processes that lead to hepatic decompensation, a serious complication of cirrhosis. The trial enrolls 100 adults aged 18 to 75 with cirrhosis. Participants receive either allopurinol tablets or a placebo, and researchers measure blood markers of gut barrier function and microbial translocation to see if the drug changes these pathways.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allopurinol, a drug that lowers uric acid levels
What this could lead to
If allopurinol helps, it could offer a low-cost way to slow liver decompensation in people with cirrhosis and reduce hospitalizations.
What could go wrong
This is an early-phase trial with 100 participants, so results may not hold in larger groups. Allopurinol can cause allergic reactions and other side effects in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

100 people

The number who actually took part.

Started

Jun 2023

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18-75 both sex Exclusion Criteria: * active GIT bleeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhoses, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhoses, liver

Contacts and locations

Locations

  • Tanta University

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.